The overexpression of AXL and its ligand Gas6 is also associated with EGFR activation and acquired resistance to the EGFR tyrosine kinase inhibitor (EGFR-TKI) in EGFR-mutated NSCLC cells [7]. The gene discussed is GAS6; the disease is non-small cell lung carcinoma.